Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Clinical trial NCT04903119 · RECRUITING

Trial details

NCT number: NCT04903119
Sponsor: Rina Plattner
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Metastatic Melanoma BRAF Gene Mutation

Start date: 2022-06-01
Primary completion: 2028-07-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.